• Indole-3-pyruvic Acid: Applied Protocols in Plant and Immune

  2026-06-18

  Indole-3-pyruvic acid (IPA) is a crucial intermediate for both plant hormone biosynthesis and mammalian immunomodulation. This article delivers actionable workflows, troubleshooting insights, and experimental enhancements that set IPA apart as a versatile reagent for advanced plant and biomedical research.

• E. coli Uracil-DNA Glycosylase (UDG): Protocol and Lab Use

  2026-06-18

  E. coli Uracil-DNA Glycosylase (UDG) addresses uracil contamination in DNA samples, enhancing PCR amplification fidelity and supporting DNA repair research. This product is not suitable for RNA, oligonucleotides shorter than six bases, or any clinical or diagnostic use.

• Dabigatran in Translational Coagulation: From Molecular Mech

  2026-06-17

  Explore Dabigatran's unique advantages as a direct thrombin inhibitor for advanced coagulation research. This article offers deep scientific insight, protocol parameters, and practical guidance for optimizing stroke and thrombosis models.

• Influenza Hemagglutinin (HA) Peptide: Precision in Protein P

  2026-06-17

  Unlock robust, high-yield protein detection and purification with the Influenza Hemagglutinin (HA) Peptide from APExBIO. This guide distills best practices, advanced use-cases, and troubleshooting strategies for leveraging the HA tag peptide in cutting-edge molecular biology and cancer research.

• ETS1 Regulates SUMOylation-Dependent Mitophagy in BPD Models

  2026-06-16

  The reference study reveals that ETS1 acts as a critical transcriptional regulator mitigating bronchopulmonary dysplasia (BPD) by targeting the SENP2/HSPA8/FUNDC1 axis and inhibiting mitochondrial damage-induced autophagy. These findings clarify how sumoylation-dependent mitophagy mechanisms can be manipulated to improve neonatal lung outcomes, suggesting new molecular targets for intervention.

• Phosbind Biotin LC: Practical Guide for Phosphorylation Dete

  2026-06-16

  Phosbind Biotin LC addresses the challenge of detecting phosphorylated proteins in Western Blot workflows when phospho-specific antibodies are unavailable or insufficient. It is optimal for PVDF membranes and protocols requiring sequence-independent detection but should not be employed in aqueous-only systems or for long-term storage of working solutions.

• Lambda Protein Phosphatase: Precision Tools for Circadian Pr

  2026-06-15

  Explore how Lambda Protein Phosphatase (RNase-free) enables high-precision analysis of phosphorylation-dependent circadian biology. This article reveals new assay strategies and deeper mechanistic insights for advanced proteomics.

• Foretinib (GSK1363089): Mechanistic Leverage for Translation

  2026-06-15

  This thought-leadership article explores how Foretinib (GSK1363089), a potent ATP-competitive multikinase inhibitor, advances translational cancer research. Blending mechanistic insight with practical strategy, it examines Foretinib’s broad kinase inhibition profile, its impact on tumor cell growth and metastasis, and the evolving best practices for in vitro and in vivo experimentation. The discussion draws on recent advances in drug response evaluation, notably the nuanced assessment approaches championed by Schwartz (2022), and positions Foretinib as a cornerstone reagent for researchers seeking robust, clinically relevant oncology models.

• WY-14643 (Pirinixic Acid): Applied Protocols for Metabolic R

  2026-06-14

  WY-14643 (Pirinixic Acid) is a selective PPARα agonist that enables precise modulation of lipid metabolism and inflammation in advanced metabolic and tumor microenvironment research. This article delivers actionable workflows, troubleshooting strategies, and evidence-based guidance to maximize assay reproducibility and translational impact.

• CX-5461: Translational Strategy for RNA Polymerase I Inhibit

  2026-06-13

  This thought-leadership article explores the mechanistic rationale, experimental evidence, and translational potential of CX-5461—an orally bioavailable RNA polymerase I inhibitor—for targeting ribosome biogenesis in solid tumors. Drawing upon recent research in cervical and other cancers, it provides actionable insights for translational researchers, highlights best-practice protocols, and situates CX-5461 within the evolving landscape of cancer therapeutics. The article bridges product intelligence with strategic experimental guidance and spotlights APExBIO’s CX-5461 as a critical tool for advancing cancer research.

• (-)-Arctigenin as a Precision MEK1 Inhibitor: Experimental M

  2026-06-12

  (-)-Arctigenin distinguishes itself as a nanomolar MEK1 inhibitor, enabling reproducible modulation of NF-κB and MAPK/ERK pathways in inflammation, neuroprotection, and cancer. This guide details experimental workflows, troubleshooting strategies, and translational insights—including how to leverage recent discoveries in breast cancer metastasis modeling with APExBIO’s high-purity Arctigenin.

• IMPDH Inhibition with Merimepodib: Transforming Translationa

  2026-06-12

  This thought-leadership article explores the mechanistic, strategic, and workflow implications of Merimepodib (VX-497)—a selective, noncompetitive, and orally bioavailable IMPDH inhibitor—in translational research. Drawing on new evidence from veterinary virology and oncology, it synthesizes actionable insights for researchers targeting cancer, immunological disorders, and emerging viral pathogens. The article uniquely bridges cross-domain findings, particularly highlighting host metabolism as a therapeutic vulnerability, and provides detailed protocol guidance for experimentalists.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-06-11

  This article reviews the development of novel allosteric inhibitors targeting pyruvate dehydrogenase kinase 4 (PDK4) as outlined in a recent medicinal chemistry study. The findings demonstrate the design and optimization of compound 8c, showing potent in vitro PDK4 inhibition and promising efficacy in metabolic, allergic, and oncology models, with potential implications for targeted therapy development.

• PTEN mRNA Innovations: Overcoming Drug Resistance in Cancer

  2026-06-11

  This thought-leadership article explores how next-generation in vitro transcribed mRNA tools—specifically EZ Cap™ Human PTEN mRNA (ψUTP)—empower translational researchers to address persistent challenges in cancer biology, such as trastuzumab resistance. By weaving mechanistic insights, experimental validation, and actionable guidance, the article demonstrates the strategic value of mRNA stability enhancement and immune evasion in preclinical and translational workflows. It also contextualizes recent landmark studies and highlights APExBIO's product innovation while offering a forward-looking perspective on the clinical relevance and future applications of PTEN mRNA delivery platforms.

• Fluconazole as a Fungal Cytochrome P450 Enzyme 14α-Demethyla

  2026-06-10

  Fluconazole’s precision as a fungal cytochrome P450 enzyme 14α-demethylase inhibitor enables robust antifungal susceptibility testing and mechanistic research into drug resistance. This article translates recent breakthroughs in autophagy-mediated Candida albicans biofilm resistance into actionable experimental workflows using APExBIO’s research-grade Fluconazole.

449 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page